

2016 EMERGING THERAPIES FOR PBC, NASH AND ESLD SEMINAR SERIES

Seattle, Washington – March 5, 2016

Conference Location	Seattle Science Foundation 550 17th Ave James Tower, Suite 600 Seattle, WA 98122	Phone : (206) 732-6500 www.seattlesciencefoundation.org
----------------------------	--	--

Parking at the Conference The Seattle Science Foundation is located on the sixth floor of the James Tower at Swedish Medical Center/Cherry Hill. Parking is available in the garage on 16th Avenue between Cherry and Jefferson at a maximum fee of \$16.50 per day.

There is also on-street, metered parking on all roads surrounding Swedish Medical Center.

Driving Directions From I-5 (northbound and southbound), take the James Street exit. James will become Cherry Street. Travel east on Cherry Street to the intersection of Cherry and 16th Ave.
Turn right (south) onto 16th Avenue. Turn right into the entrance of the parking garage.

Please allow 5-7 minutes walking time from the 16th Avenue Garage to the James Tower at 550 17th Street

Seminar Agenda and Syllabus Information Registration and breakfast begin at **7:30 a.m.** in the **Seattle Science Foundation’s Teleconference Room**. Please check signage for any last minute room changes.

The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the *App* will be provided to participants in advance of the seminar. WiFi will be available without charge.

7:30 am	<i>Registration, Continental Breakfast & View Exhibits</i>
8 am	End Stage Liver Disease: Case Presentations, Managing Complications - Treatment of hepatic encephalopathy - Treatment of ascites, edema and hepatorenal syndrome - Management of esophageal varices
8:45 am	Hepatocellular Carcinoma - Screening diagnostic serum assays and imaging tests - Diagnosis without histology - Treatment and management options
9:30 am	Liver Transplantation - Listing criteria - MELD Exceptions - Long Term Complications - Outcomes
10:15 am	<i>Break & View Exhibits</i>
10:30 am	- New Treatments for PBC - Ursodiol - Obeticholic Acid
11:15 am	- PSC - Epidemiology - Predicting Outcomes - Improving Survival
12:00 pm	<i>Lunch and View Exhibits</i>

12:45 pm	<ul style="list-style-type: none"> - NAFLD, LAL and NASH - Epidemiology - Demographics - Diagnosis - Conventional treatments
1:30 pm	<ul style="list-style-type: none"> - NASH Treatments in Development - Obeticholic Acid - Elafibranor (GTR505) - Others
2:15 pm	<ul style="list-style-type: none"> - Case Presentations: - PBC - LAL causing fatty liver disease - NASH
3 pm	<i>Final Comments and Adjourn</i>

Attendance Policies

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

CME Information

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of 6.0 *AMA PRA Category 1 Credit(s)*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 7.2 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-16-878. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)TM organizations accredited by ACCME.


**Your Seminar
Faculty**



KRIS V. KOWDLEY, M.D.

Dr. Kowdley is internationally recognized as a clinician, educator and researcher in the area of liver disease and has presented his research on liver diseases at more than 135 national and international meetings and scientific symposia. He is the author of over 375 articles, book chapters, reviews and commentaries in this area and has been published in the *Annals of Internal Medicine*, *Archives of Surgery*, *Gastroenterology*, *Hepatology*, *American Journal of Physiology*, *New England Journal of Medicine*, and among other professional publications.

Dr. Kowdley has extensive experience in clinical trials in all areas of liver disease, ranging from hepatitis C, cholestatic liver disease, nonalcoholic steatohepatitis and hepatitis B. He has been a principal investigator in several NIDDK-sponsored clinical trials in primary biliary cirrhosis, primary sclerosing cholangitis and is a member of executive committee of the nonalcoholic steatohepatitis clinical research network (NASH CRN).



ROBERT CARITHERS, M.D.,

Dr. Robert Carithers is a Professor of Medicine at the University of Washington in Seattle, Washington.

In 1990 he became the medical director of the liver transplant program at the University of Washington Medical Center in Seattle. His primary clinical and research interests include the management of patients with cirrhosis, hepatitis B, hepatitis C, alcoholic liver disease, hepatocellular carcinoma, and liver transplantation.

He is a fellow of the American College of Physicians, American College of Gastroenterology, and the American Association for the Study of Liver Diseases.



ANNE M. CROGHAN, MN, ARNP

Anne Croghan is a Nurse Practitioner working with patients with liver disease at Swedish Medical Center in Seattle, Washington. A native of Washington DC, Anne has practiced in an academic medical center, a specialty group practice and at Veteran's Administration Medical Center.

Her clinical practice has assisted patients in the evaluation and treatment of hepatitis C, hepatitis B, HCV/HIV co-infected, HBV/HIV co-infected, fatty liver disease, pre- and post-liver transplant patients, and patients with hepatocellular carcinoma. She has also worked as an investigator on multiple clinical trials for viral hepatitis.

Ms. Croghan has also published articles in several recognized medical and nursing journals.